Elizabeth Mily Leads T1D Fund in New Era of Impact Investing
People | Jan 08, 2025 | EIN
The T1D Fund has appointed Elizabeth Mily as CEO, signaling a new phase of strategic leadership to enhance its impact investment efforts in the fight against type 1 diabetes. With a background in pharma and healthcare investment banking, Mily brings over 30 years of experience, having previously held executive roles at Bristol Myers Squibb, Barclays, and Goldman Sachs. Her appointment aligns with the T1D Fund’s focus on expanding equity investments and building strategic partnerships with leading biopharma, venture capital, and foundations. The T1D Fund aims to leverage its relationships with the Helmsley Charitable Trust and Breakthrough T1D to drive forward innovative therapies with curative potential. Under Mily’s leadership, the Fund intends to expand its investment team and ecosystem, fostering research and innovation in type 1 diabetes treatments and elevating public awareness of the ongoing need for cures.
Sectors
- Biopharmaceuticals
- Impact Investing
- Venture Capital
Geography
- United States – The article mentions Boston and organizations such as the Helmsley Charitable Trust which are based in the United States.
Industry
- Biopharmaceuticals – The article discusses efforts to develop therapies for type 1 diabetes, which is a key focus of the biopharmaceutical industry.
- Impact Investing – The T1D Fund is described as an impact investment fund aimed at life-changing solutions for type 1 diabetes.
- Venture Capital – The article highlights the T1D Fund's strategy of forming partnerships with venture capital firms in its investment activities.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Elizabeth Mily | CEO | People | Recently appointed CEO of the T1D Fund, bringing extensive expertise in strategy and investment banking. |
| T1D Fund | Impact Investment Fund | Charity | An impact investment fund focusing on research and development of treatments for type 1 diabetes. |
| Bristol Myers Squibb | Former Employer | Company | Elizabeth Mily's former employer where she handled strategy and business development. |
| Goldman Sachs | Former Employer | Company | One of the firms where Elizabeth Mily held senior roles. |
| Barclays | Former Employer | Company | A previous employer of Elizabeth Mily, mentioned for her role in strategy and transactions. |
| Thermo Fisher Scientific | Former Employer | Company | A company where Elizabeth Mily held a senior role. |
| Solventum Corporation | Board Member | Company | Company on whose board Elizabeth Mily serves, particularly in audit and quality committees. |
| Ampersand Biomedicines | Board Member | Company | A private Flagship Pioneering portfolio company where Elizabeth Mily serves on the board. |
| Helmsley Charitable Trust | Partner Organization | Charity | Funding organization supporting T1D research and partnered with T1D Fund. |
| Breakthrough T1D | Partner Organization | Charity | formerly JDRF, a partner aligned with T1D Fund's strategic objectives. |